Clinical Trial Update: A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease. [Phase 2]

View source ↗

Summary

A Phase II study evaluating enzalutamide and ARv7 in metastatic castration-resistant prostate cancer with visceral metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Carcinoma Prostate | Phase 2 | Status: COMPLETED